drugset / Trial / NCT01519414

Tivantinib in Treating Patients With Metastatic Prostate Cancer

NCT01519414

Phase 2 Completed 78 enrolled National Cancer Institute (NCI)
RandomizedCrossoverDouble-blindTreatment

Summary

This randomized phase II trial studies how well tivantinib works compared to placebo in treating patients with metastatic prostate cancer. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2012-01-11
Primary completion
2015-08-18
Completion
2015-08-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Tivantinib Small molecule Oral